Twist Bioscience Corporation

41.05+2.94+7.71%Vol 2.29M1Y Perf -68.90%
Jun 24th, 2022 16:00 DELAYED
BID41.05 ASK41.33
Open38.69 Previous Close38.11
Pre-Market- After-Market39.00
 - -  -2.05 -4.99%
Target Price
38.25 
Analyst Rating
Moderate Buy 2.50
Potential %
-6.82 
Finscreener Ranking
★★★     49.86
Insiders Trans % 3/6/12 mo.
-83/-94/-99 
Value Ranking
★★★★     55.66
Insiders Value % 3/6/12 mo.
-43/-81/-99 
Growth Ranking
★★★     52.56
Insiders Shares Cnt. % 3/6/12 mo.
-31/-67/-97 
Income Ranking
 —    -
Price Range Ratio 52W %
13.91 
Earnings Rating
Strong Buy
Market Cap2.31B 
Earnings Date
5th Aug 2022
Alpha0.03 Standard Deviation0.22
Beta1.18 

Today's Price Range

38.0141.30

52W Range

25.07139.99

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Buy
Performance
1 Week
31.74%
1 Month
16.72%
3 Months
-9.60%
6 Months
-51.42%
1 Year
-68.90%
3 Years
39.63%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
TWST41.052.94007.71
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Financial StrengthValueIndustryS&P 500US Markets
7.20
7.90
0.07
0.09
-961.00
Leverage Ratio 1.20
ProfitabilityValueIndustryS&P 500US Markets
38.60
-122.50
-115.00
-259.20
-
RevenueValueIndustryS&P 500US Markets
163.11M
2.90
46.59
71.69
Earnings HistoryEstimateReportedSurprise %
Q02 2022-1.26-1.241.59
Q01 2022-1.08-0.9115.74
Q04 2021-0.80-0.84-5.00
Q03 2021-0.76-0.82-7.89
Q02 2021-0.76-0.78-2.63
Q01 2021-0.74-0.722.70
Q04 2020-0.71-0.5423.94
Q03 2020-0.72-0.676.94
Earnings Per EndEstimateRevision %Trend
6/2022 QR-1.304.41Positive
9/2022 QR-1.374.20Positive
9/2022 FY-4.852.41Positive
9/2023 FY-4.72-5.83Negative
Next Report Date5th Aug 2022
Estimated EPS Next Report-1.30
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume2.29M
Shares Outstanding56.26K
Shares Float55.73M
Trades Count31.06K
Dollar Volume91.74M
Avg. Volume1.36M
Avg. Weekly Volume1.68M
Avg. Monthly Volume1.30M
Avg. Quarterly Volume1.12M

Twist Bioscience Corporation (NASDAQ: TWST) stock closed at 41.05 per share at the end of the most recent trading day (a 7.71% change compared to the prior day closing price) with a volume of 2.29M shares and market capitalization of 2.31B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 525 people. Twist Bioscience Corporation CEO is Emily M. Leproust.

The one-year performance of Twist Bioscience Corporation stock is -68.9%, while year-to-date (YTD) performance is -46.96%. TWST stock has a five-year performance of %. Its 52-week range is between 25.07 and 139.99, which gives TWST stock a 52-week price range ratio of 13.91%

Twist Bioscience Corporation currently has a PE ratio of -8.40, a price-to-book (PB) ratio of 2.03, a price-to-sale (PS) ratio of 10.75, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -22.58%, a ROC of -23.64% and a ROE of -25.98%. The company’s profit margin is -%, its EBITDA margin is -115.00%, and its revenue ttm is $163.11 Million , which makes it $2.90 revenue per share.

Of the last four earnings reports from Twist Bioscience Corporation, there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-1.30 for the next earnings report. Twist Bioscience Corporation’s next earnings report date is 05th Aug 2022.

The consensus rating of Wall Street analysts for Twist Bioscience Corporation is Moderate Buy (2.5), with a target price of $38.25, which is -6.82% compared to the current price. The earnings rating for Twist Bioscience Corporation stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Twist Bioscience Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Twist Bioscience Corporation has a Buy technical analysis rating based on Technical Indicators (ADX : 21.09, ATR14 : 3.05, CCI20 : 211.20, Chaikin Money Flow : 0.09, MACD : 0.46, Money Flow Index : 68.36, ROC : 33.32, RSI : 67.80, STOCH (14,3) : 98.46, STOCH RSI : 1.00, UO : 69.31, Williams %R : -1.54), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Twist Bioscience Corporation in the last 12-months were: Emily M. Leproust (Option Excercise at a value of $939 901), Emily M. Leproust (Sold 170 438 shares of value $19 379 839 ), James M. Thorburn (Option Excercise at a value of $787 638), James M. Thorburn (Sold 48 122 shares of value $3 634 192 ), Jan Johannessen (Option Excercise at a value of $210 000), Jan Johannessen (Sold 15 253 shares of value $1 372 296 ), Keith L. Crandell (Sold 90 000 shares of value $9 630 753 ), Nicolas M. Barthelemy (Buy at a value of $250 096), Patrick Finn (Option Excercise at a value of $471 190), Patrick Finn (Sold 27 281 shares of value $2 682 882 ), Patrick Weiss (Option Excercise at a value of $514 148), Patrick Weiss (Sold 29 141 shares of value $2 952 631 ), Robert B. Chess (Sold 16 253 shares of value $1 960 606 ), William Banyai (Option Excercise at a value of $200 246), William Banyai (Sold 128 755 shares of value $13 379 043 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (50.00 %)
2 (50.00 %)
2 (50.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (25.00 %)
1 (25.00 %)
1 (25.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (25.00 %)
1 (25.00 %)
1 (25.00 %)
Summary RatingModerate Buy
2.50
Moderate Buy
2.50
Moderate Buy
2.50

Twist Bioscience Corporation

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.

CEO: Emily M. Leproust

Telephone: +1 800 719-0671

Address: 681 Gateway Boulevard, South San Francisco 94080, CA, US

Number of employees: 525

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

62%38%

Bearish Bullish

60%40%

Bearish Bullish

56%44%

TipRanks News for TWST

Mon, 09 May 2022 01:21 GMT Twist Bioscience (TWST) Gets a Buy Rating from Barclays

- TipRanks. All rights reserved.

Sun, 08 May 2022 15:21 GMT Twist Bioscience (TWST) Gets a Hold Rating from SVB Securities

- TipRanks. All rights reserved.

Sat, 12 Feb 2022 09:13 GMT Twist Bioscience (TWST) Gets a Sell Rating from J.P. Morgan

- TipRanks. All rights reserved.

News

Stocktwits